CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 179 enrolled
Drug / intervention
High Dose Influenza vaccine +3 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02872311
NCT02872311N/ACompleted
CompareCT.gov

Open-Label, Randomized Study of Immune Response to Licensed Influenza Vaccines in Adults 65-74 Years of Age (US Flu Vaccine Effectiveness Serologic Study, 2016-17 and 2017-18)

Marshfield Clinic Research Foundation·interventional·Posted Aug 19, 2016·Updated Dec 10, 2025

In Brief

A clinical study evaluating High Dose Influenza vaccine, Adjuvanted Influenza vaccine, and 2 other interventions for Immune Response. Completed, enrolled 179 participants across 1 site.

Detailed Summary

This is an open-label, randomized trial in up to 210 adults aged 65-74 years to evaluate the immune response to consecutive influenza vaccination across 2 seasons. Participants will be randomized to receive 1 of 3 licensed and recommended vaccines in the first year; 2 arms will receive the same vaccination in the second year and the third arm will be randomized again to 1 of 3 licensed vaccines. All participants will have pre and post-vaccination serum blood draws for a total of 6 draws over 18 months.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsImmune Response
CountriesUnited States
CollaboratorsCenters for Disease Control and Prevention

Timeline

N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedAug 19, 2016
Enrollment StartSep 1, 2016
Primary CompletionApr 1, 2018
Study CompletionSep 1, 2018
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 9.9 years ago

Interventions

High Dose Influenza vaccinebiological

Licensed and FDA approved Fluzone HD vaccine to be administered to study participants

Adjuvanted Influenza vaccinebiological

Licensed and FDA approved FluAd vaccine to be administered to study participants

Standard Dose Influenza vaccinebiological

Licensed and FDA approved Fluvirin vaccine to be administered to study participants

Recombinant Influenza vaccinebiological

Licensed and FDA approved FluBlok vaccine to be administered to study participants